{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+SC&page=2",
    "query": {
      "intervention": "placebo SC",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+SC&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-23T06:55:01.590Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06113328",
      "title": "A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-segmental Vitiligo"
      ],
      "interventions": [
        {
          "name": "MK-6194",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 169,
      "start_date": "2023-11-27",
      "completion_date": "2025-07-30",
      "has_results": true,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-09-23T06:55:01.590Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Hot Springs, Arkansas • Los Angeles, California + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06113328"
    },
    {
      "nct_id": "NCT01991509",
      "title": "Safety and Bioavailability of IV and SC LBR-101",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bioavailability and Pharmacokinetics"
      ],
      "interventions": [
        {
          "name": "LBR-101 IV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LBR-101 SC",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 36,
      "start_date": "2013-10",
      "completion_date": "2015-01",
      "has_results": false,
      "last_update_posted_date": "2015-03-04",
      "last_synced_at": "2026-09-23T06:55:01.590Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01991509"
    },
    {
      "nct_id": "NCT00423501",
      "title": "A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus Type 2"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "taspoglutide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 306,
      "start_date": "2007-02",
      "completion_date": "2007-11",
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-09-23T06:55:01.590Z",
      "location_count": 10,
      "location_summary": "Washington D.C., District of Columbia • Woodstock, Georgia • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Woodstock",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00423501"
    },
    {
      "nct_id": "NCT03524092",
      "title": "A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "Mirikizumab SC",
          "type": "DRUG"
        },
        {
          "name": "Mirikizumab IV",
          "type": "DRUG"
        },
        {
          "name": "Placebo SC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 1328,
      "start_date": "2018-10-19",
      "completion_date": "2025-02-17",
      "has_results": true,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-09-23T06:55:01.590Z",
      "location_count": 57,
      "location_summary": "Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 51 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Litchfield Park",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03524092"
    },
    {
      "nct_id": "NCT05355805",
      "title": "Hidradenitis Suppurativa Phase 2b Study of Izokibep",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hidradenitis Suppurativa"
      ],
      "interventions": [
        {
          "name": "Izokibep",
          "type": "DRUG"
        },
        {
          "name": "Placebo to izokibep",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ACELYRIN Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 205,
      "start_date": "2022-05-05",
      "completion_date": "2024-02-21",
      "has_results": true,
      "last_update_posted_date": "2025-06-03",
      "last_synced_at": "2026-09-23T06:55:01.590Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • Encino, California • Fountain Valley, California + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05355805"
    },
    {
      "nct_id": "NCT05533372",
      "title": "MAD Study of IA-14069",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy",
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "IA-14069",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ILAb Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 78,
      "start_date": "2022-10-10",
      "completion_date": "2025-10-15",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-09-23T06:55:01.590Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05533372"
    },
    {
      "nct_id": "NCT06290128",
      "title": "A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Inflammatory Demyelinating Polyradiculoneuropathy",
        "Polyneuropathy, Inflammatory Demyelinating, Chronic"
      ],
      "interventions": [
        {
          "name": "Riliprubart",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 109,
      "start_date": "2024-07-12",
      "completion_date": "2027-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-09-23T06:55:01.590Z",
      "location_count": 28,
      "location_summary": "Homewood, Alabama • Los Angeles, California • Orange, California + 24 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06290128"
    },
    {
      "nct_id": "NCT01597245",
      "title": "A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "80 mg ixekizumab Dosing Regimen",
          "type": "DRUG"
        },
        {
          "name": "50 mg etanercept",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1224,
      "start_date": "2012-05-18",
      "completion_date": "2019-06-18",
      "has_results": true,
      "last_update_posted_date": "2020-06-26",
      "last_synced_at": "2026-09-23T06:55:01.590Z",
      "location_count": 41,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 38 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01597245"
    },
    {
      "nct_id": "NCT04856930",
      "title": "A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hidradenitis Suppurativa"
      ],
      "interventions": [
        {
          "name": "Imsidolimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Vanda Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 149,
      "start_date": "2021-07-07",
      "completion_date": "2022-12-14",
      "has_results": true,
      "last_update_posted_date": "2025-09-22",
      "last_synced_at": "2026-09-23T06:55:01.590Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Fountain Valley, California • Northridge, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04856930"
    },
    {
      "nct_id": "NCT04134728",
      "title": "Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Arthritis, Rheumatoid"
      ],
      "interventions": [
        {
          "name": "GSK3196165 (Otilimab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sarilumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo to GSK3196165/ Sarilumab",
          "type": "DRUG"
        },
        {
          "name": "csDMARDs",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 550,
      "start_date": "2019-10-31",
      "completion_date": "2022-02-01",
      "has_results": true,
      "last_update_posted_date": "2023-07-17",
      "last_synced_at": "2026-09-23T06:55:01.590Z",
      "location_count": 46,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Covina",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04134728"
    }
  ]
}